| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
13.04.2017 US 201762485355 P
28.08.2017 US 201715688320
28.08.2017 WO PCT/US2017/048890
|
| (43) |
Date of publication of application: |
|
04.11.2020 Bulletin 2020/45 |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
18718572.3 / 3609471 |
| (73) |
Proprietor: Onconova Therapeutics, Inc. |
|
Newtown, PA 18940 (US) |
|
| (72) |
Inventor: |
|
- MANIAR, Manoj
Fremont, CA California 94539 (US)
|
| (74) |
Representative: V.O. |
|
P.O. Box 87930
2508 DH Den Haag
2508 DH Den Haag (NL) |
| (56) |
References cited: :
|
| |
|
|
- RAZA AZRA ET AL: "Oral Rigosertib (ON 01910.Na) Treatment Produces A Encouraging Rate
Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients;
A Genomic Methylation Profile Is Associated With Responses", BIOSIS, BIOSCIENCES INFORMATION
SERVICE, PHILADELPHIA, PA, US, 1 November 2013 (2013-11-01), XP002788716,
- NAVADA SHYAMALA C ET AL: "Combination of Oral Rigosertib and Injectable Azacitidine
in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study",
BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 2 December 2016 (2016-12-02),
XP002788717,
- NAVADA SHYAMALA C ET AL: "A Phase II Study of the Combination of Oral Rigosertib and
Azacitidine in Patients with Myelodysplastic Syndromes (MDS)", BIOSIS, BIOSCIENCES
INFORMATION SERVICE, PHILADELPHIA, PA, US, 1 December 2015 (2015-12-01), XP002788718,
- RAMI S. KOMROKJI ET AL: "Phase I clinical trial of oral rigosertib in patients with
myelodysplastic syndromes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 162, no. 4, 21 June
2013 (2013-06-21) , pages 517-524, XP055483608, GB ISSN: 0007-1048, DOI: 10.1111/bjh.12436
|
|
